OM336

DRUG3 trials

Sponsors

Medical University Of Vienna, Ouro Medicines

Conditions

AIHA - Cold Autoimmune Hemolytic AnemiaAIHA - Warm Autoimmune Hemolytic AnemiaEnd stage renal failureITP - Immune ThrombocytopeniaIdiopathic Inflammatory Myopathy (IIM)Sjogrens Disease

Phase 1

OM336 in Autoimmune Cytopenias

RecruitingNCT07083960

Ouro MedicinesAIHA - Cold Autoimmune Hemolytic Anemia, AIHA - Warm Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia

Start: 2025-08-01End: 2027-09-30Target: 32Updated: 2025-09-30

OM336 in Seropositive Autoimmune Diseases

Not yet recruitingNCT07229144

Ouro MedicinesIdiopathic Inflammatory Myopathy (IIM), Sjogrens Disease

Start: 2025-11-30End: 2028-03-31Target: 39Updated: 2025-11-14

Phase 2

An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates

WithdrawnCTIS2025-523222-40-00

Medical University Of ViennaEnd stage renal failure

Target: 6Updated: 2026-05-04

Related Papers

Trial in progress: A phase 1b, open-label, multiple ascending dose study of OM336, a novel BCMAxCD3 T cell engager, in patients with relapsed/refractory autoimmune cytopenias (NCT07083960)

Blood2025-11-03